secwatch.observer — SEC 8-K summary
======================================

Issuer:     Xilio Therapeutics, Inc. (XLO)
CIK:        0001840233
Form:       8-K
Filed at:   2023-05-25T23:59:59+00:00
Accession:  0001558370-23-010481
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Xilio reports encouraging Phase 1 data for XTX101: partial response in PD-L1 neg NSCLC, favorable safety at RP2D
--------------------------------------------------------------------------------

- Preliminary data from Phase 1 trial of XTX101 in 25 patients with advanced solid tumors; RP2D set at 150 mg Q6W.
- Partial response observed at nine weeks in a PD-L1 negative advanced NSCLC patient with hepatic metastases, continuing on treatment.
- At RP2D, no Grade 4/5 treatment-related AEs, no colitis or infusion reactions; only Grade 3 AE was diarrhea (resolved).
- Evidence of tumor-selective activation: low unmasked drug in peripheral circulation and minimal immune activation in periphery.
- Plans to explore XTX101 in combination with PD-(L)1 in immunotherapy-resistant tumor types, including MSI-stable CRC.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1840233/000155837023010481/0001558370-23-010481-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1840233/000155837023010481/xlo-20230525x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-23-010481

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer